BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Location: Israel, Center District, Ness Ziona
Employees: 51-200
Total raised: $56M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Baruch Fut... | baruch.vc |
| - | OrbiMed | orbimed.co... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.02.2019 | Series B | $32M | - |
| 15.05.2017 | Series A | $24M | OrbiMed |
Mentions in press and media 14
| Date | Title | Description | Source |
| 18.03.2024 | BiomX Announces Closing of the Acquisition of Adaptive Phage... | - | globenewsw... |
| 06.03.2024 | BiomX Announces Entry into Merger Agreement with Adaptive Ph... | - | globenewsw... |
| 26.07.2021 | BiomX Inc. Announces $15 Million Registered Direct Offering | NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or t... | marketscre... |
| 24.05.2021 | BIOMX INC. BiomX : Earnings Document | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTER... | marketscre... |
| 21.02.2019 | Daily funding roundup - February 21st, 2019 | SensorFlow raised a $2.7M; Zoba raised $3M; Back to the Roots raised $3M: WaitWhat raised $4.3 Senso... | vator.tv/n... |
| 21.02.2019 | Term Sheet — Thursday, February 21 | LYFT PREDICTIONS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boun... | fortune.co... |
| 20.02.2019 | BiomX nets $32M to engineer bacteria-killing viruses for IBD... | BiomX has raised $32 million to continue preclinical development of its customized phage cocktail th... | fiercebiot... |
| 20.02.2019 | BiomX nets $32M to engineer bacteria-killing viruses for IBD... | BiomX has raised $32 million to continue preclinical development of its customized phage cocktail th... | fiercebiot... |
| 20.02.2019 | BiomX Raises $32 Million in Series B Financing | BiomX Ltd., a microbiome company developing customized phage therapies, today announced the closing ... | citybizlis... |
| 20.02.2019 | BiomX Raises $32M in Series B Financing | BiomX Ltd., a Ness Ziona, Israel-based microbiome company developing customized phage therapies, clo... | finsmes.co... |
Show more